Analysts believe SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price will rise 29.45% from current levels

The trading price of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) floating lower at last check on Wednesday, Apr 07, closing at $9.81, -5.55% lower than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $9.00 and $10.15. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 1.71. In examining the 52-week price action we see that the stock hit a 52-week high of $19.38 and a 52-week low of $1.52. Over the past month, the stock has gained 24.33% in value.

SELLAS Life Sciences Group, Inc., whose market valuation is $138.71 Million at the time of this writing, is expected to release its quarterly earnings report May 12, 2021- May 17, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.27 per share this quarter, however they have predicted annual earnings per share of -$1.06 for 2021 and -$0.97 for 2022. It means analysts are expecting annual earnings per share growth of -0.5% this year and -0.08% next year.

On the technical side, indicators suggest SLS has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned SLS a recommendation rating is 1. Out of them, no one rate it a Hold, while 1 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged SELLAS Life Sciences Group, Inc. (SLS) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that SLs price is currently -2.12% off the SMA20 and 4.85% off the SMA50. The RSI metric on the 14-day chart is currently showing 51.28, and weekly volatility stands at 13.03%. When measured over the past 30 days, the indicator reaches 12.02%. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s beta value is currently sitting at 1.71, while the Average True Range indicator is currently displaying 1.08. With analysts defining $12-$12 as the low and high price targets, we arrive at a consensus price target of $12 for the trailing 12-month period. The current price is about 29.45% off the estimated low and 29.45% off the forecast high, based on this estimate. Investors will be thrilled if SLs share price rises to $12, which is the median consensus price. At that level, SLs share price would be +29.45% above current price.

To see how SELLAS Life Sciences Group, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: SLS stock’s performance was -5.55% at last check in today’s session, and +532.9% in the past year, while Amgen Inc (AMGN) has been trading -0.15% in recent session and positioned +21.27% higher than it was a year ago. Another comparable company Bristol-Myers Squibb Company (BMY) saw its stock trading 0.35% higher in today’s session but was up +11.62% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -5.55% today while its price kept rising at 532.9% over the past year. SELLAS Life Sciences Group, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.23 and Bristol-Myers Squibb Company’s 0. Also during today’s trading, the S&P 500 Index has surged 0.16%, while the Dow Jones Industrial also saw a positive session, up +0.01% today.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


An evaluation of the daily trading volume of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) indicates that the 3-month average is 1.87 Million. However, this figure has increased over the past 10 days to an average of 469.62 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Currently, records show that 15.08 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 0.47% of outstanding shares, whereas institutions hold 10.42%. The stats also highlight that short interest as of March 14, 2021, stood at 852.11 Million shares, resulting in a short ratio of 0.98 at that time. From this, we can conclude that short interest is 5.98% of the company’s total outstanding shares. It is noteworthy that short shares in March were down slightly from the previous month’s figure, which was 960.42 Million. However, since the stock’s price has seen +68.85% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

We save you valuable time every morning with our early morning newsletter!... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.